Transthyretin Amyloid Cardiomyopathy

PALO ALTO, Calif., August 31, 2026 BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on medicines for...

CAMBRIDGE, United Kingdom, July 9, 2026 AstraZeneca and Ionis Pharmaceuticals have announced results from the Phase III CARDIO-TTRansform trial...

PALO ALTO, Calif., July 2, 2026 BridgeBio Pharma, Inc. announced new post-hoc analyses published in Circulation: Heart Failure showing...